Skip to content

Silence Therapeutics plc

SLN SLNCF

CIK 0001479615 · Pharmaceutical Preparations · Nasdaq, OTC

← back to feed
Revenue (TTM)
$947K
−98.7% YoY Q1 Apr 2026
Net Income (TTM)
−$91.8M
−95.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.65
−90.9% YoY Q1 Apr 2026
Gross Margin
77.4%
Q1 Apr 2026
Operating Margin
-9,963.4%
Q1 Apr 2026
Net Margin
-9,693.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$62.33M
Q1 Apr 2026
Cash
$5.66M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
141.7M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings